Is Akerna Corp a Smart Choice in Drug Manufacturers - Specialty Generic Monday - InvestorsObserver
| 123330 Stock | KRW 23,000 1,750 8.24% |
About 55% of Genic's investors are presently thinking to get in. The analysis of current outlook of investing in Genic Co suggests that some traders are interested regarding Genic's prospects. The current market sentiment, together with Genic's historical and current headlines, can help investors time the market. In addition, many technical investors use Genic stock news signals to limit their universe of possible portfolio assets.
Genic |
Is Akerna Corp a Smart Choice in Drug Manufacturers - Specialty Generic Monday InvestorsObserver
Read at news.google.com
 |
Genic Fundamental Analysis
We analyze Genic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Genic is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Genic Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genic stock to make a market-neutral strategy. Peer analysis of Genic could also be used in its relative valuation, which is a method of valuing Genic by comparing valuation metrics with similar companies.
Peers
Genic Related Equities
| 041020 | Polaris Office | 3.45 | ||||
| 041460 | Korea Electronic | 2.59 | ||||
| 057050 | Hyundai Home | 1.32 | ||||
| 008060 | Daeduck Electronics | 0.30 | ||||
| 095270 | Wave Electronics | 0.39 | ||||
| 004590 | Hankook Furniture | 0.74 | ||||
| 290720 | FoodNamoo | 3.19 |
Complementary Tools for Genic Stock analysis
When running Genic's price analysis, check to measure Genic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genic is operating at the current time. Most of Genic's value examination focuses on studying past and present price action to predict the probability of Genic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genic's price. Additionally, you may evaluate how the addition of Genic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |